RNAZ
|Transcode Therapeutics Inc
NASDAQ
USD 7.57
+0.59|+8.45%
Current Price
USD 7.57
Change
+USD 0.59 (8.45%)
P/E Ratio
Dividend Yield
Market Cap
6.02M
Volume
60,507
Open
USD 7.00
Previous Close
USD 6.98
52-Week High
USD 1293.51
52-Week Low
USD 6.15
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Thomas A. Fitzgerald M.B.A.
Employees:7
Headquarters:Boston, USA
Website:www.transcodetherapeutics.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions